Savara(US:SVRA) Globenewswire·2025-10-08 15:10Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to alleged violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI, which has led to significant investor losses [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Savara, with a deadline of November 7, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Savara and its executives made false and misleading statements regarding the MOLBREEVI BLA, impacting investor decisions [6]. Group 2: Financial Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [7]. - The allegations suggest that the delay in regulatory approval for MOLBREEVI may necessitate Savara to raise additional capital, further impacting its financial stability [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [5]. - The firm is actively seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].